Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00025246
Other study ID # NCI-2012-03079
Secondary ID ACOSOG-Z9000U10C
Status Completed
Phase Phase 2
First received October 11, 2001
Last updated February 19, 2013
Start date September 2001

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth


Description:

PRIMARY OBJECTIVES:

I. To ascertain whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with STI571 have prolonged survival compared to historical controls.

SECONDARY OBJECTIVES:

I. To determine the 2 and 5-year prevalence of recurrence in patients treated with adjuvant STI571 following complete resection of high-risk primary GIST.

II. To obtain from patients with GIST: tumor tissue (before therapy with STI571 and at the time of recurrence), blood specimens (before therapy with STI571), and serum specimens (before therapy with STI571, after completing therapy with STI571, and at the time of recurrence) for scientific correlative analyses.

III. To assess the toxicity of oral STI571 therapy when used in the adjuvant setting.

OUTLINE:

Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 10 years.


Recruitment information / eligibility

Status Completed
Enrollment 89
Est. completion date
Est. primary completion date November 2007
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Patient must have an ECOG/Zubrod performance status of = 2

- Patient must have a diagnosis of high-risk primary GIST; NOTE: High risk is defined as tumor size = 10 cm in maximum dimension, or the presence of tumor rupture before or during surgery, intraperitoneal hemorrhage or multifocal (< 5) intraperitoneal tumors

- Patient must have undergone complete gross resection (includes R0 [negative microscopic margins] and R1 [positive microscopic margins] resections) of a primary GIST within 70 days prior to registration

- Patient must have a histologic diagnosis of GIST that is confirmed by central pathology review

- Patient's tumor must stain positive for the Kit receptor tyrosine kinase on immunohistochemistry as determined by the central pathologist using the Dako (Dako Corp., Carpinteria, CA) anti-CD 117 antibody

- Patient must have a chest x-ray completed within 28 days prior to registration

- Patient must have a post-operative CT scan with IV and PO contrast or MRI with contrast (if allergic to CT contrast) of abdomen and pelvis within 28 days prior to registration

- Creatinine = 1.5 times the institution ULN

- WBC = 2,000/mm^3

- Platelet = 100,000/mm^3

- Total bilirubin = 1.5 times the institution ULN

- AST and ALT = 2.5 times the institution ULN

- Female of childbearing potential must have negative serum pregnancy test

- Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study related procedures

- If patient is a cancer survivor, each of the following criteria must apply:

- Patient has undergone potentially curative therapy for all prior malignancies,

- No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone)

- Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies

Exclusion Criteria:

- Patient has received post-operative chemotherapy

- Patient has received post-operative radiation therapy

- Patient has received post-operative investigational treatment

- Patient has received prior therapy with STI571

- Patient has had an active infection requiring antibiotics within 14 days prior to registration

- Patient has objective evidence of residual disease on the post-operative CT scan or MRI of the abdomen or pelvis

- Patient, if female and breastfeeding; NOTE: It is not known whether STI571 or its metabolites are excreted in human milk; however, in lactating female rats administered 100 mg/kg, a dose approximately equal to the maximum clinical dose of 800 mg/day based on body surface area, STI571 and/or its metabolites were extensively excreted in milk; it is estimated that approximately 1.5% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight; because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women should be advised against breastfeeding while taking STI571

- Patient has New York Heart Association class 3 or 4 cardiac disease

- Patient is taking full dose warfarin; NOTE: The use of mini-dose warfarin (1 mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
imatinib mesylate
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States American College of Surgeons Oncology Group Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls Up to 5 years No
Secondary Prevalence of recurrence free survival Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. 2 years No
Secondary Prevalence of recurrence Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. 5 years No
Secondary Overall survival Marginal point and two-sided 95% (pointwise) confidence bands, based on Kaplan-Meier estimator will be produced. Up to 5 years No
Secondary Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria Up to 10 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04933669 - Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors Phase 2
Completed NCT01769248 - Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle N/A
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Completed NCT01110668 - Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Phase 2
Terminated NCT00091078 - Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery Phase 2
Active, not recruiting NCT00265798 - Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate Phase 2
Recruiting NCT04143048 - A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
Recruiting NCT02931981 - Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor N/A
Not yet recruiting NCT02576080 - Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Phase 3
Recruiting NCT01389583 - A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients Phase 2
Recruiting NCT00777504 - Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase 4
Completed NCT00769782 - Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00764595 - Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor Phase 2
Completed NCT00098579 - Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery Phase 1
Completed NCT00005862 - SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas Phase 2
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Recruiting NCT02776878 - A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST N/A
Completed NCT01751919 - A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) Phase 1
Completed NCT01267695 - Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor Phase 2
Terminated NCT00956072 - Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate Phase 3